[1]杨欢,石玉红,冉海凤等.促红细胞生成素的生理功能及生成来源[J].中国临床药理学与治疗学,2021,26(04):434-443. [2]Peng Bo,Kong Gangcheng,Yang Chengetal. Erythropoietin and its derivatives: from tissue protection to immune regulation.[J]. Cell death & disease,2020,11(2). [3]Senthil Velan Bhoopalan,Lily Jun-shen Huang,Mitchell J. Weiss. Erythropoietin regulation of red blood cell production: from bench to bedside and back[J]. F1000Research,2020,9. [4]Jelkmann Wolfgang. Physiology and pharmacology of erythropoietin.[J]. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie,2013,40(5). [5]Wenger R H,Kurtz A. Erythropoietin [J]. Compreh Physiol,2011,1: 1759-1794. [6]Asano H, Hotta T, Ichihara M et al. Growth analysis of marrow CD34 - positive hematopoietic progenitor cells in patients with myelodysplasticsyndromes Leukemia 1994;8:833-838. [7]Sawada K,Sato N,Notoya Aetal.Proliferation and differentiation of myelodysplastic CD34+ cells: phenotypic subpopulations of marrow CD34+ cells.[J]. Blood,1995,85(1). [8]Backx B, Broeders L. Lowenberg B Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome Blood 1992;80:1213-1217 [9]Hoefsloot LH, Van Amelsvoort MP, Broeders LC etal. Erythropoietin- induced activation of STAT5 is impaired in the myelodysplastic syndromeBlood1997;89:1690-1700 [10]Backx B,Broeders L,Hoefsloot L H et al. Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand.[J].Leukemia,1996,10(3). [11]Parker JE,Fishlock KL,Mijovic A et al. ‘Low - risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti - apoptotic bcl - 2 - related proteins Br J Haematol 1998;103:1075-1082 [12]Fontenay-Roupie M,Bouscary D,Guesnu M et al. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction.[J]. British journal ofhaematology,1999,106(2). [13]Sophie Park,Charikleia Kelaidi,Rosa Sapena et al. Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients[J]. Leukemia Research,2010,34(11). [14]Moyo V,Lefebvre P,Duh MS et al. Erythropoiesis- stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta - analysis AnnHematol2008;87:527-536 [15]Park Sophie,Grabar Sophie,Kelaidi Charikleia et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.[J]. Blood,2008,111(2). [16]Cheson Bruce D,Greenberg Peter L,Bennett John M et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.[J]. Blood,2006,108(2). [17]Stasi R,Brunetti M,Terzoli E et al. Once - weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive toconventional dosing Ann Oncol 2004; 15:1684-1690 [18]Mundle Suneel,Lefebvre Patrick,Vekeman Francis et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.[J]. Cancer,2009,115(4). [19]Itzykson R,Ayari S,Vassilief D et al. Is there a role for all - trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases Leukemia 2009;23:673-678 [20]Houston Brett L,Jayakar Jennifer,Wells Richard A et al. A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.[J]. Annals of hematology,2017,96(12). [21]Greenberg Peter L,Stone Richard M,Al-Kali Aref et al.Myelodysplastic Syndromes,Version 2017,NCCN Clinical Practice Guidelines inOncology.[J] .Journal of the National Comprehensive Cancer Network:JNCCN,2017,15(1). 作者简介：麦迪乃•阿卜杜乃比(1997-)，女，新疆人，在读研究生，主要从事血液病学相关研究。 通讯作者：石雨薇(1969-)，女，山东人，主任医师，副教授，硕士研究生导师，主要从事血液肿瘤及慢性病管理
